Skip to main content

BioCryst Pharmaceuticals Value Stock - Dividend - Research Selection

Biocryst pharmaceuticals

ISIN: US09058V1035 , WKN: 896047

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

2025-04-10
BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-04-04
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of April 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing

BioCryst to Present at Upcoming Investor Conference

2025-04-02
RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotech

High Growth Tech Stocks In The US Market With Promising Potential

2025-03-27
The United States market has remained flat over the past week but has seen an 8.5% increase over the past year, with earnings projected to grow by 14% annually. In this context, identifying high-growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and market trends, offering promising potential in a dynamic economic landscape.

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

2025-03-18
Key Insights Given the large stake in the stock by institutions, BioCryst Pharmaceuticals' stock price might be...

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

2025-03-01
We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stands against the other small-cap stocks. The S&P 500 index has reached its all-time highs, achieving returns of over 20% for the second consecutive year […]

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

2025-02-27
Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

2025-02-26
After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

2025-02-26
The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results

2025-02-26
There's been a notable change in appetite for BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) shares in the week since...